Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia

Figure 4

Effect of rimonabant on HDL-cholesterol, triglycerides, and waist circumference at each visit and at 9 months.

(a)

(b)

(c)